SCNX_OUT_1 [2025-04-01 06:31:58 -0400] 3008 Bytes | 865 tokens | Cum: 865 tkns (10.81% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Scienture (SCNX) which is at 1.67 up from 1.44. So, I pulled together a bunch of data for you to look over real fast. It's still early, 6:31:57 AM on Tue Apr 01, 2025 -0400. So, what's the verdict? You're the expert!

Here's the first list of news for Scienture:

C1 - Mar-25-25 08:05AM - SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization
C2 - Mar-19-25 08:05AM - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
C3 - Mar-18-25 08:05AM - SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.
C4 - Mar-06-25 07:40AM - SCIENTURE to commercially launch REZENOPY , a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
C5 - Jan-21-25 08:05AM - Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics
C6 - Dec-17-24 08:05AM - Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025
C7 - Dec-10-24 08:05AM - Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
C8 - Nov-26-24 04:05PM - Scienture Holdings, Inc. Announces Private Placement of $3 Million of 10% Secured Convertible Debentures as Initial Tranche of $12 Million Offering and Entry into $50 Million Equity Line of Credit Agreement

Prior AI Reports for SCNX:
1. 2025-03-21 – Score: 20 – Target: 2.0800 – Highs: 2.1600 / 2.0600 / 2.00
scienture-holdings-struggles-amidst-sharp-sales-decline-and-negative-earnings
2. 2025-03-19 – Score: 1 – Target: 1.8905 – Highs: 2.0693 / 1.9000 / 2.16
challenging-outlook-amid-signs-of-investor-interest

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Scienture (SCNX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

SCNX_OUT_3 [2025-04-01 06:32:03 -0400] 1101 Bytes | 347 tokens | Cum: 1214 tkns (15.17% of 8k)
==========================================================================

Showing C3 (chunk 1 of 12): C3:
**SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.**
Date: Mar-18-25 08:05AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/18/3044475/0/en/SCIENTURE-announces-the-U-S-FDA-Approval-of-its-NDA-for-SCN-102-to-be-launched-as-ArbliTM-losartan-potassium-Oral-Suspension-10mg-mL-The-global-market-for-losartan-potassium-was-ap.html

March 18, 2025 08:05 ET| Source:Scienture Holdings, Inc.Scienture Holdings, Inc.

TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- –SCIENTURE HOLDINGS, INC.NASDAQ: SCNX),a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCNX_OUT_5 [2025-04-01 06:32:03 -0400] 1039 Bytes | 288 tokens | Cum: 1615 tkns (20.19% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-25T12:27:32Z - SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a l...
A2 - 2025-03-25T12:27:53Z - SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a l...
A3 - 2025-03-25T12:05:00Z - SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a l...
A4 - 2025-03-19T21:06:24Z - 12 Health Care Stocks Moving In Wednesday's After-Market Session - Akebia Therapeutics (NASDAQ:AKBA)...
A5 - 2025-03-19T17:06:06Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Biodexa Pharmaceuticals (NASDAQ:BDRX)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SCNX_OUT_7 [2025-04-01 06:32:06 -0400] 1098 Bytes | 289 tokens | Cum: 1906 tkns (23.82% of 8k)
==========================================================================

Showing A1 (chunk 1 of 9): A1:
**SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization | Taiwan News | Mar. 25, 2025 20:05**Date: 2025-03-25Source: {'uri': 'taiwannews.com.tw', 'dataType': 'news', 'title': 'Taiwan News'}URL: https://taiwannews.com.tw/en/news/6068278TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce Michele Rath as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, LLC, a wholly owned subsidiary of the Company, leading and managing Scienture, LLC's commercial opera

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCNX_OUT_9 [2025-04-01 06:32:07 -0400] 440 Bytes | 120 tokens | Cum: 2101 tkns (26.26% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-21T13:05:00Z - Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SCNX_OUT_11 [2025-04-01 06:32:10 -0400] 848 Bytes | 243 tokens | Cum: 2346 tkns (29.33% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/21/3012635/0/en/Scienture-Holdings-Inc-Announces-Dr-Narasimhan-Mani-s-Participation-in-the-8th-Annual-Conference-of-The-Society-for-the-Study-of-Xenobiotics.htmlScienture Holdings, Inc., a specialty pharmaceutical company, announced that its President, Dr. Narasimhan Mani, will participate as a speaker and panelist at the 8th Annual Conference of The Society for the Study of Xenobiotics in India.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCNX_OUT_13 [2025-04-01 06:32:11 -0400] 1088 Bytes | 287 tokens | Cum: 2724 tkns (34.05% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-25 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER ##TABLE_END

The following discussion of the Companys historical performance and financial condition should be read together with the CONS financial statements and related notes...

S2 - 2025-03-21 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 17, 2025, Scienture Holdings, Inc., a Delaware corporation (the Company) entered into a consulting agreement (the Consulting Agrmt) with Draper, Inc., a Nevada corporation (Draper). Pursuant to the Consulting A...

S3 - 2025-03-10 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On March 4, 2025, Scienture Holdings, Inc., through its wholly-owned subsidiary Scienture, LLC (the Company), entered into an Exclusive Commercial and Supply Agrmt (the Agrmt) with Summit Biosciences Inc., a wholly-...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SCNX_OUT_15 [2025-04-01 06:32:12 -0400] 1098 Bytes | 235 tokens | Cum: 2961 tkns (37.01% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ##TABLE_END

The following discussion of the Companys historical performance and financial condition should be read together with the consolidated financial statements and related notes in the section entitled Item 8. Financial Statements and Supplemental Data of this Annual Report. This discussion contains forward-looking statements based on the views and beliefs of our management, as well as assumptions and estimates made by our management. See the section entitled Cautionary Statement Regarding Forward-Looking Information above. These statements by their nature are subject to risks and uncertainties and are influenced by various factors. As a consequence, actual results may differ materially from those in the forward-looking statements. See Item 1A. Risk Factors of this Annual Report for

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

SCNX_OUT_17 [2025-04-01 06:32:20 -0400] 4188 Bytes | 1192 tokens | Cum: 4155 tkns (51.94% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 232,554 | Perf Month: -45.66% | Option/Short: No / Yes | Sales Y/Y TTM: -98.47% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 2.94M | Perf Quarter: -80.77% | Short Float: 5.63% | ROE: -45.84% |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.08 | Index: - | Short Ratio: 0.12 | ROI: -25.83% |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 38.19 | Market Cap: 18.02M | Short Interest: 0.36M | Sales Surprise: 9.28% |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.43 | Shs Outstand: 8.75M | Beta: 2.78 | EPS Surprise: -286.67% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: -16.93% | Shs Float: 6.43M | Sales Q/Q: -97.74% | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: -48.09% | Inst Own: 0.75% | Sales past 5Y: -17.00% | Earnings: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -79.58% | Insider Own: 48.62% | Employees: 19 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: -24.61% | Insider Trans: 0.00% | Debt/Eq: 0.04 | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 136643, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 9065798.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.44
Average Volume: 8234646.1
30-Day High: 2.48
30-Day Low: 1.24

[Detailed Financials: TTM 2024]
- Total Assets: $104,853,805.0
- Total Liabilities: $25,781,684.0
- Total Equity: $79,072,121.0
- Current Assets: $6,305,477.0
- Current Liabilities: $7,906,893.0

[Income Statement: TTM 2024]
- Revenue: $136,643.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 2.69

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $307,782

[Detailed Financials: FY 2024]
- Total Assets: $104,853,805.0
- Total Liabilities: $25,781,684.0
- Total Equity: $79,072,121.0
- Current Assets: $6,305,477.0
- Current Liabilities: $7,906,893.0

[Income Statement: FY 2024]
- Revenue: $136,643.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 2.69

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $307,782
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

SCNX_OUT_19 [2025-04-01 06:32:22 -0400] 676 Bytes | 167 tokens | Cum: 4568 tkns (57.10% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

SCNX_IN_21 [2025-04-01 06:32:22 -0400] 126 Bytes | 29 tokens | Cum: 4625 tkns (57.81% of 8k)
==========================================================================

====================================
[2025-04-01 06:32:22] # Analysis Completed
Elapsed Time: 24.90 seconds